Bioventus Inc. Stock Price, News & Analysis

Bioventus (Nasdaq: BVS) will report third quarter fiscal 2025 financial results before the market opens on Tuesday, November 4, 2025.

Management will host a conference call at 8:30 a.m. Eastern Time the same day. Investors can dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call, or join a live webcast and view accompanying materials on the company Investor Relations website at https://ir.bioventus.com/. The webcast will be archived and available for replay through November 3, 2026.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has announced its participation in the upcoming Morgan Stanley Global Healthcare Conference. Mark Singleton, the company's Senior Vice-President and Chief Financial Officer, will engage in a fireside chat on September 10, 2025, at 1:05 p.m. ET.

Investors can access a live webcast of the presentation through the "Investors" section of Bioventus's website at www.bioventus.com, with a replay option available after the event.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has announced its participation in the upcoming Canaccord Genuity Global Growth Conference. Rob Claypoole, the company's President and CEO, will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 p.m. ET.

The presentation will include a question-and-answer session and will be accessible via live webcast through the "Investors" section of Bioventus's website. A replay of the event will be made available on the company's website following the presentation.

Bioventus (Nasdaq: BVS) reported Q2 2025 financial results with revenue of $147.7 million, showing a 2.4% decline but 6.2% organic growth. The company achieved diluted EPS of $0.11 compared to a loss of $0.40 in the prior year, while non-GAAP EPS grew 31% to $0.21.

Key highlights include FDA clearance for TalisMann and StimTrial for chronic peripheral nerve pain treatment, representing a $2 billion market opportunity. The company's segments showed mixed performance: Pain Treatments grew 1.5% to $73.3M, Surgical Solutions increased 11.4% to $52.7M, while Restorative Therapies declined 31.6% to $21.6M due to business divestiture.

Bioventus reiterated its 2025 guidance with expected revenue of $560-570 million and non-GAAP EPS of $0.64-0.68.

Bioventus (Nasdaq: BVS) has secured a new $400 million Senior Secured Credit Agreement, comprising a $300 million term loan and a $100 million revolving credit facility, maturing on July 31, 2030. The agreement represents significant improvements over their 2019 Credit Agreement, featuring a 75 basis point reduction in interest margin, generating over $2 million in annual interest savings.

Key enhancements include an increase in revolving credit facility from $40 million to $100 million, and a reduction in annual term loan amortization from 10% to 5%. The company used the proceeds to repay its outstanding $333 million loan balance under the 2019 agreement, utilizing the new term loan, $30 million from the revolving facility, and $3 million cash on hand.

Bioventus (Nasdaq: BVS) has received FDA 510(k) clearances for two new Peripheral Nerve Stimulation (PNS) products: TalisMann™ and StimTrial™. These innovative solutions target the rapidly growing PNS market, which is projected to exceed $500 million by 2029 with over 20% annual growth.

TalisMann™ combines electric field conduction technology with an integrated pulse generator for treating chronic nerve pain, while StimTrial™ enables physicians to evaluate patient response to PNS therapy. The company plans a limited commercial release in Q3 2025, followed by a broader rollout in early 2026.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its second quarter fiscal year 2025 earnings release and conference call. The company will announce its financial results before market open on Wednesday, August 6, 2025, followed by a management-hosted conference call at 8:30 a.m. Eastern Time.

Investors can participate by dialing 1-800-715-9871 (Conference ID: 1859022) or accessing the webcast through the company's investor relations website. The webcast recording will remain available for replay until August 5, 2026.

[]

Bioventus (BVS) reported Q1 2025 financial results with revenue of $123.9 million, showing a 4.3% decline from the prior year, while organic revenue grew 5.0%. The company's net loss improved to $0.04 per share from $0.08 in the prior year, with non-GAAP earnings increasing 33% to $0.08 per share. Pain Treatments revenue grew 3.9% to $58.9M, Surgical Solutions increased 7.0% to $45.2M, while Restorative Therapies declined 35.3% to $19.7M due to the Advanced Rehabilitation business divestiture. The company maintained its 2025 guidance, projecting revenue of $560-570M, Adjusted EBITDA of $112-116M, and Non-GAAP EPS of $0.64-0.68.

Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its first quarter fiscal year 2025 financial results announcement for May 6, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time on the same day, where management will discuss the results and provide a business update.

Investors can participate by dialing 1-833-636-0497 and referencing the Bioventus Conference Call. A live webcast and accompanying materials will be available on the company's investor relations website, with replay access until May 5, 2026.